SecBot SecBot
SECBOTREPLAY Home › Report › CLDX

CLDX · Celldex announced three presentations at EAACI 2026: two flash talks on…

Celldex Therapeutics, Inc. · PRESS-RELEASE filed Jun 10, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 10, 2026 at 16:01 ET

Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold urticaria, plus a late-breaking poster on first-in-human Phase 1 results for CDX-622, a bispecific targeting TSLP and mast cells. This is a routine scientific conference update with no new efficacy or safety data disclosed, providing no material stock-moving catalyst.

  • Three presentations to be given at EAACI Annual Congress, June 12-15, 2026, in Istanbul, Türkiye
  • Two flash talks on barzolvolimab: one on long-term off-treatment angioedema improvement in CSU, another on psychometric validation of WI-NRS in cold urticaria
  • Late-breaking poster on Phase 1 first-in-human results of CDX-622 (bispecific targeting TSLP and mast cells via SCF) in healthy volunteers
  • Barzolvolimab is in Phase 3 studies for CSU and ColdU/SD, and Phase 2 studies for prurigo nodularis and atopic dermatitis

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access